Results 71 to 80 of about 4,829,888 (359)
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. [PDF]
, 2020 Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed.
Ballas, Samir K
core +1 more source
Identification of New Drug Candidates Against \u3cem\u3eBorrelia burgdorferi\u3c/em\u3e Using High-Throughput Screening [PDF]
, 2016 Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that .300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of
Babar, Mustafeez Mujtaba +9 more
core +3 more sources
FDA Drug Approval Summaries: Oxaliplatin
The Oncologist, 2004 Abstract Learning Objectives After completing this course, the reader will be able to: Describe the safe and effective use of oxaliplatin in patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of ...
Amna, Ibrahim +5 more
openaire +2 more sources
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Value in Health, 2020 OBJECTIVES Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been ...
B. Feinberg +5 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Saudi Pharmaceutical Journal, 2018 Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs.
Bander Balkhi +2 more
doaj +1 more source
Pharmacy, 2022 The “breakthrough therapy” designation (BTD) is a recent mechanism implemented by the United States Food and Drug Administration (FDA) to expedite access to drugs that address unmet needs.
Megan C. Herink +4 more
doaj +1 more source
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. [PDF]
, 2019 BackgroundA previous analysis of 113 National Comprehensive Cancer Network® (NCCN®) recommendations reported that NCCN frequently recommends beyond Food and Drug Administration (FDA)-approved indications (44 off-label recommendations) and claimed that ...
Benson, AB +8 more
core
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
FDA Disclosure of Safety and Effectiveness Data: A Legal and Policy Analysis [PDF]
, 1979 Syftet med studien är att genom analys av förskollärares berättelser beskriva hur barns sociala samspel och lek kan påverkas och utvecklas. Den empiriska studien baserar sig på åtta intervjuer med förskollärare som delat med sig av sina erfarenheter i ...
Appelqvist, Madeleine +1 more
core +4 more sources